Efficacy and Safety Study of SH T 586 in Combination With Rituximab to Treat Low-Grade NHL

Exclusion Criteria

• •Patients with infectious disease, serious complications, serious gastrointestinal symptoms, serious bleeding tendency, serious CNS symptoms, fever \</=38 °C, interstitial pneumonia or pulmonary fibrosis, active other malignancies, autoimmune hemolytic anemia or the history of the disease, or glaucoma.
• •Patients who are positive for HBs antigen, HCV antibody, or HIV antibody.
• •Patients who received G-CSF or transfusion within 1 week before the registration.
• •Patients with the history of allergies to purine nucleoside analogue.
• •Patients who experienced serious hypersensitivity or anaphylaxis to rituximab or mouse protein-derived products.
• •Patients who had ever received prior therapy with fludarabine phosphate injection, pentostatin, cladribine, SH T 586, blood stem cell transplant, or monoclonal antibody therapy other than rituximab to NHL (including radioimmunotherapy).
• •Patients who had progressive disease within 6 months of receiving therapy including rituximab.
• •Women who are pregnant, of childbearing potential, or lactating.
• •Patients who do not agree to practice contraception.